Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
71°
Sunny
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Apellis Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
December 28, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
December 14, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
December 11, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
November 04, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 01, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
October 25, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
October 20, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
October 17, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
October 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
October 02, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
September 25, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
September 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 30, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
August 29, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
August 22, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
July 31, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
July 30, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
July 29, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
July 24, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 10, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.